Summary of scheduled assessment and follow-up during the study
Evaluations | Visit 0 | Visit 1–8 | Visit 9 | Visit 10 | Visit 11 | Visit 12 | Visit 13 |
Discharge | Month: 0–6 after discharge | Month: 12 after discharge | Month: 18 after discharge | Month: 24 after discharge | Month: 30 after discharge | Month: 36 after discharge | |
Informed consent | X | ||||||
Inclusion/exclusion criteria | X | ||||||
Randomisation | X | ||||||
Demographic data | X | ||||||
Clinical data | X | ||||||
Blood sample | X | X | |||||
BMI | X | X | X | ||||
Sarcopenia | X | X | X | ||||
Haematological indicators | X | X | X | ||||
QoL (EORTC QLQ-C30) | X | X | X | ||||
ω-3 PUFAs intakes in diet | X | X | |||||
Chemotherapy tolerance | X | ||||||
Chemotherapy toxicity | X | ||||||
Adherence to interventions | X | ||||||
Adverse events | X | ||||||
Unplanned readmission | X | ||||||
CT or MRI | X | X | X | X | X | X | |
Tumour markers | X | X | X | X | X | X | |
Endoscopy | X | X | X | ||||
DFS | X | ||||||
OS | X |
BMI, body mass index; DFS, disease-free survival; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; OS, overall survival; QoL, quality of life.